GENERIC NAME: alemtuzumab
BRAND NAME: Campath
GENERIC AVAILABLE: No
USES: Alemtuzumab is used alone for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)
WARNING: (BLACK BOX WARNING)
- Serious, including fatal, reduction in blood cells, underdevelopment of bone marrow, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving alemtuzumab. The risk of pancytopenia is increased by single doses of alemtuzumab greater than 30 mg or doses greater than 90 mg per week.
- Alemtuzumab may cause serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold alemtuzumab for serious infusion reactions. Gradually increase alemtuzumab to the recommended dose at the beginning of treatment and after interruption of therapy for 7 or more days.
- Alemtuzumab may cause serious, including fatal, bacterial, viral, fungal, and protozoan infections. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections.
Common side effects include:
- Low blood cell counts
- Infusion reactions
- Cytomegalovirus (CMV) and other infections
Other side effects include:
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.